Intravitreal triamcinolone acetonide and secondary ocular hypertension.
Jonas
Jost
J
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de
Heatley
Gregg
G
Spaide
Richard
R
Varma
Rohit
R
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008269:Macular Edema / Q000188:drug therapy; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000188:drug therapy; D014222:Triamcinolone Acetonide / Q000009:adverse effects* / Q000627:therapeutic use; D014792:Visual Acuity; D014822:Vitreous Body
D000959:Antihypertensive Agents; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide